Individuals infected with HIV-1 require lifelong antiretroviral therapy, because interruption of
treatment leads to rapid rebound viraemia. Here we report on a phase 1b clinical trial in …

Antiretroviral therapy is highly effective in suppressing human immunodeficiency virus (HIV).
However, eradication of the virus in individuals with HIV has not been possible to date …

HIV-1 infection remains a public health problem with no cure. Anti-retroviral therapy (ART) is
effective but requires lifelong drug administration owing to a stable reservoir of latent …

Interruption of combination antiretroviral therapy (ART) in HIV-1-infected individuals leads to
rapid viral rebound. Here we report the results of a phase IIa open label clinical trial …

Monotherapy of HIV-1 infection with single antiretroviral agents is ineffective because error-
prone HIV-1 replication leads to the production of drug-resistant viral variants …

To determine the protective potential of the humoral immune response against HIV-1 in vivo
we evaluated the potency of three neutralizing antibodies (2G12, 2F5 and 4E10) in …

HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was
largely ineffective in pre-clinical and clinical settings and was therefore abandoned …

The latent viral reservoir is the critical barrier for the development of a cure for HIV-1
infection. Previous studies have shown direct antiviral activity of potent HIV-1 Env-specific …

Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency
virus type 1 (HIV-1) infection, little progress has been made in generating an effective HIV-1 …

Novel broadly neutralizing antibodies targeting HIV-1 hold promise for their use in the
prevention and treatment of HIV-1 infection. Pre-clinical results have encouraged the …